CARMEL, Ind., April 10, 2026 (GLOBE NEWSWIRE)-- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic ...
CARMEL, Ind., May 15, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children ...
NeurAxis announced strong Q1 2025 results, with a 39% revenue increase and expanded payer coverage, while operating loss improved. NeurAxis, Inc. reported a strong first quarter for 2025, with ...
CARMEL, Ind., May 22, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...
Shares of NeurAxis, Inc. NRXS have lost 8.6% since the company reported results for the quarter ended Sept. 30, 2025, underperforming the S&P 500 Index’s 1.7% decline over the same period. The stock ...
CARMEL, Ind., May 27, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results